Logo image
Se connecter
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial
Article de revue   Open Access   Avec comité de lecture

Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial

Subodh Verma, Nitish Dhingra, Javed Butler, Stefan Anker, Joao Pedro Ferreira, Gerasimos Filippatos, James Januzzi, Carolyn Lam, Naveed Sattar, Barbara Peil, …
The Lancet. Diabetes & Endocrinology
11/2021

Fichiers et liens (1)

url
Find in HALAfficher

Détails

Logo image